Redwood City, CA, United States
Redwood City, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Facet Biotech | Date: 2010-09-28

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.


Patent
Facet Biotech and PDL BioPharma Inc. | Date: 2010-03-26

Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.


Patent
Facet Biotech | Date: 2010-06-08

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.


Patent
Facet Biotech | Date: 2010-10-28

The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR.


The use of CD56bright NK cell counts and IL-2 receptor protein expression as predictive biomarkers for the efficacy of anti-IL-2R antibody treatment in patients diagnosed with multiple sclerosis.


The present invention provides chimeric and humanized antibodies that specifically recognize alpha5beta1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.


Compositions and methods for treating MM are provided herein.


Patent
Facet Biotech | Date: 2010-03-31

The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.


The use of CD56bright NK cell counts as a biomarker for the efficacy of anti-IL-2R antibody treatment in patients diagnosed with multiple sclerosis.


The use of HLA-DR^(+)CD4^(+) T cell counts as biomarker for the efficacy of daclizumab treatment in patients diagnosed with multiple sclerosis.

Loading Facet Biotech collaborators
Loading Facet Biotech collaborators